A5044899339- Lymphoma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Histone Deacetylase Inhibitors Research
- Chronic Myeloid Leukemia Treatments
- Cancer, Hypoxia, and Metabolism
- Protein Degradation and Inhibitors
- T-cell and Retrovirus Studies
- Cutaneous lymphoproliferative disorders research
- Viral-associated cancers and disorders
- Acute Lymphoblastic Leukemia research
- Pneumonia and Respiratory Infections
- Bacterial Infections and Vaccines
- Multiple Myeloma Research and Treatments
- RNA Interference and Gene Delivery
- Epigenetics and DNA Methylation
- Cell death mechanisms and regulation
- Carcinogens and Genotoxicity Assessment
- ATP Synthase and ATPases Research
- CNS Lymphoma Diagnosis and Treatment
- Ubiquitin and proteasome pathways
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Advanced biosensing and bioanalysis techniques
- Mitochondrial Function and Pathology
VA Long Beach Healthcare System
2020-2025
University of California, Irvine
2021-2025
The University of Texas MD Anderson Cancer Center
2015-2024
United States University
2024
University Clinic of Traumatology
2023
University of California, Irvine Medical Center
1990-2022
Columbia University Irving Medical Center
2018-2021
Columbia University
2019
NewYork–Presbyterian Hospital
2019
New York Hospital Queens
2019
Abstract Despite high initial response rates, acute myeloid leukemia (AML) treated with the BCL-2–selective inhibitor venetoclax (VEN) alone or in combinations commonly acquires resistance. We performed gene/protein expression, metabolomic and methylation analyses of isogenic AML cell lines sensitive resistant to VEN, identified activation RAS/MAPK pathway, leading increased stability higher levels MCL-1 protein, as a major acquired mechanism VEN sustained survival maintained mitochondrial...
// Polina Matre 1, * , Juliana Velez Rodrigo Jacamo 1 Yuan Qi 2 Xiaoping Su Tianyu Cai Steven M. Chan 3 Alessia Lodi 4 Shannon R. Sweeney Helen Ma Richard Eric Davis 5 Natalia Baran Torsten Haferlach 6 Xiaohua 7 Elsa Renee Flores Doriann Gonzalez Sergej Konoplev 8 Ismael Samudio 9 Courtney DiNardo Ravi Majeti Aaron D. Schimmer 10 Weiqun Li 11 Taotao Wang Stefano Tiziani Marina Konopleva Departments of Leukemia, The University Texas MD Anderson Cancer Center, Houston, TX, USA Bioinformatics...
Targeted therapies designed to exploit specific molecular pathways in aggressive cancers are an exciting area of current research. Mixed Lineage Leukemia (MLL) mutations such as the t(4;11) translocation cause leukemias that refractory conventional treatment. The produces MLL/AF4 fusion protein activates key target genes through both epigenetic and transcriptional elongation mechanisms. In this study, we show patient cells express high levels BCL-2 highly sensitive treatment with...
Abstract T-cell acute lymphoblastic leukemia (T-ALL) is commonly driven by activating mutations in NOTCH1 that facilitate glutamine oxidation. Here we identify oxidative phosphorylation (OxPhos) as a critical pathway for cell survival and demonstrate direct relationship between , elevated OxPhos gene expression, acquired chemoresistance pre-leukemic leukemic models. Disrupting with IACS-010759, an inhibitor of mitochondrial complex I, causes potent growth inhibition through induction...
BCL-XL and BCL-2 are key anti-apoptotic proteins validated cancer targets. 753B is a novel BCL-XL/BCL-2 proteolysis targeting chimera (PROTAC) that targets both to the von Hippel-Lindau (VHL) E3 ligase, leading BCLX L/BCL-2 ubiquitination degradation selectively in cells expressing VHL. Because platelets lack VHL expression, spares on-target platelet toxicity caused by first-generation dual inhibitor navitoclax (ABT-263). Here, we report pre-clinical single-agent activity of against...
To characterize the prevalence of hypoxia in leukemic bone marrow, its association with metabolic and transcriptional changes blasts utility hypoxia-activated prodrug TH-302 leukemia models.Hyperpolarized magnetic resonance spectroscopy was utilized to interrogate pyruvate metabolism marrow murine acute myeloid (AML) model. Nanostring technology used evaluate a gene set defining signature normal donors. The efficacy examined vitro vivo models.Metabolic imaging has demonstrated increased...
Abstract Acute myeloid leukemia (AML) cells are highly dependent on oxidative phosphorylation (OxPhos) for survival, and they continually adapt to fluctuations in nutrient oxygen availability the bone marrow (BM) microenvironment. We investigated how BM microenvironment affects response OxPhos inhibition AML by using a novel complex I inhibitor, IACS-010759. Cellular adhesion, growth, apoptosis assays, along with measurements of expression mitochondrial DNA generation reactive species...
Abstract Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with poor outcomes conventional therapy. Nearly 100% of BPDCNs overexpress interleukin 3 receptor subunit alpha (CD123). Given that CD123 differentially expressed on the surface BPDCN cells, it has emerged as an attractive therapeutic target. UCART123 investigational product consisting allogeneic T cells expressing anti-CD123 chimeric antigen (CAR), edited TALEN ® nucleases. In this study, we...
Abstract Major depressive disorder is a leading cause of disability worldwide; identifying effective strategies to prevent depression relapse crucial. This individual participant data meta-analysis addresses whether and for whom psychological interventions can be recommended prevention major disorder. One- two-stage patient meta-analyses were conducted on 14 randomized controlled trials ( N = 1,720). The risk over 12 months was substantially lower those who received intervention versus...
<b><i>Background:</i></b> Mindfulness-based cognitive therapy (MBCT) is a potential treatment for chronic insomnia. We evaluated the efficacy of MBCT insomnia (MBCT-I) by comparing it with sleep psycho-education exercise control (PEEC) group. <b><i>Methods:</i></b> Adults primary (<i>n</i> = 216) were randomly allocated to MBCT-I or PEEC The included mindfulness and behavioural components under hygiene stimulus control, exercises....
Abstract Trial Information ClinicalTrials.gov Identifier: NCT02091063 Sponsor: Acetylon Pharmaceuticals Principal Investigator: Jennifer E. Amengual IRB Approved: Yes Lessons Learned Oral selective HDAC6 inhibitors could allow for decreased toxicity compared to pan-class inhibitors, and increased ease of use. ACY-1215 is well tolerated led disease stabilization in 50% patients treated on a twice-daily dosing schedule. Rational drug combinations with improve efficacy lymphoma. Biomarkers such...
In Vietnam veterans, exposure to military toxicants, such as Agent Orange, may be associated with lymphoid malignancies. Toxicant increase the likelihood of being diagnosed concurrent malignancies, which can occur composite, discordant, or transformed lymphomas. We conducted a large, retrospective case-control study using national VA Central Cancer Registry identify cases malignancies compared controls single and association Orange. The occurrence was rare (n = 128/32,889, 0.4%). most common...
// Qi Zhang 1, * , Ce Shi 6, Lina Han 6 Nitin Jain 1 Kathryn G. Roberts 2 Helen Ma Tianyu Cai Antonio Cavazos Yoko Tabe 3 Rodrigo O. Jacamo Hong Mu Yang Zhao 4 Jing Wang Shuo-Chieh Wu 5 Fenglin Cao Zhihong Zeng Jin Zhou Yingchang Mi 7 Elias J. Jabbour Ross Levine 8 Sarah K. Tasian 9 Charles Mullighan David M. Weinstock A. Fruman 10 and Marina Konopleva Department of Leukemia, The University Texas M.D. Anderson Cancer Center, Houston, TX, USA Pathology, St. Jude Children's Research Hospital,...
Background Salvage immunochemotherapy followed by high‐dose chemotherapy and autologous stem cell transplantation is the standard‐of‐care second‐line treatment for patients with relapsed/refractory diffuse large B‐cell lymphoma after first‐line R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). Outcomes receipt of in aggressive lymphomas who relapse or are refractory to intensive regimens (etoposide, prednisone, rituximab [R‐EPOCH], rituximab, hyperfractionated...
The peripheral T-cell lymphomas (PTCL) are rare and heterogeneous diseases characterized by an unfavorable prognosis. Chemotherapy is standard upfront treatment in most patients, but responses short-lived with few FDA-approved "novel" agents available. We sought to define the impact of these novel as single or clinical trials on outcomes patients PTCL. From January 1994 May 2019, adult PTCL who were managed at our institution included this analysis. In addition incomplete data, those...
Summary Survival outcomes for elderly lymphoma patients are disproportionally inferior to those of younger patients. We examined medication usage at diagnosis 171 (median age 70 years) with aggressive non‐Hodgkin treated between 2009 and 2014. At least one potentially inappropriate was used in 47% according the Beers Criteria, 59% experienced treatment delays and/or dose reduction 65% ≥ grade 3 treatment‐related toxicities. report here first time that use associated reduced progression‐free...